Patients with type 2 diabetes mellitus (T2DM) prescribed glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have significantly lower one-year mortality, especially those also diagnosed with obstructive sleep apnea (OSA), according to a study presented at CHEST 2025, the annual meeting of the American College of Chest Physicians, held from Oct. 19 to 22 in Chicago.
This post was originally published on this site
